A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma

Japanese Journal of Clinical Oncology

Volumn 33, Issue 2, 2003, Pages 78-85

  Takeyama, Kunihiko ^a,b   Ogura, Michinori ^c   Morishima, Yasuo ^c   Kasai, Masaharu ^d   Kiyama, Yoshio ^d   Ohnishi, Kazunori ^e   Mitsuya, Hiroaki ^f   Kawano, Fumio ^g   Masaki, Yasufumi ^h   Sasaki, Tsuneo ⁱ   Chou, Takaaki ^j   Yokozawa, Toshiya ^a,b   Tobinai, Kensei ^a   Kagami, Y ^c   Ohno, R ^e   Takiguchi, T ^h   Sai, T ^k   Mochizuki, M ^l   Yamada, H ^m   Tsutani, H ⁿ   Ohno, H ^o   Tomonaga, M ^p   more..

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d SAPPORO HOKUYU HOSPITAL   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^h KANAZAWA MEDICAL UNIVERSITY   (Japan)

ⁱ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^j Niigata Cancer Center   (Japan)

^k Iwaki Kyoritsu General Hospital   (Japan)

^l JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁿ UNIVERSITY OF FUKUI   (Japan)

^o KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^p NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

CHOP therapy; G CSF; Lenograstim; Mobilization; Non Hodgkin's lymphoma; Peripheral blood stem cell

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; PREDNISONE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; APHERESIS; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME DEFECT; FEMALE; FEVER; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERSTITIAL PNEUMONIA; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPTIMAL DRUG DOSE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; PROTEIN DEFECT; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; ADOLESCENT; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; CLONOGENIC ASSAY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METHODOLOGY; MIDDLE AGED;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONY-FORMING UNITS ASSAY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; RECOMBINANT PROTEINS; VINCRISTINE;

EID: 0037314521     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg013     Document Type: Article

References (34)

1. Gianni AM, Bregni M, Siena S, Orazi A, Stern AC, Gandola L, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990;8:768-78.
2. Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992;79: 3036-44.
3. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-94.
4. Grigg AP, Roberts A, Raunow H, Houghton S, Layton JE, Boyd AW, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995;86:4437-45.
5. Hoglund M, Smedmyr B, Simonsson B, Totterman T, Bengtsson M. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF. Bone Marrow Transplant 1996;18:19-27.
6. Akizuki S, Mizorogi F, Inoue T, Sudo K, Ohnishi A. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects. Bone Marrow Transplant 2000;26:939-46.
7. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
8. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury. J Clin Oncol 1999;17:423-9.
9. Jones HM, Jones SA, Watts MJ, Khwaja A, Mills W, Fielding A, et al. Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994;12:1693-702.
10. Olivieri A, Offidani M, Ciniero L, Cantori I, Ombrosi L, Mancini S, et al. Optimization of the yield of PBSC for autotransplantation mobilized by high-dose chemotherapy and G-CSF: Proposal for a mathematical model. Bone Marrow Transplant 1994;14:273-8.
11. Aurlien E, Holte H, Pharo A, Kvaloy S, Jakobsen E, Smeland EB, et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998;21:873-8.
12. Russell NH, McQuaker G, Stainer C, Byrne JL, Haynes AP. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998;22:935-40.
13. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
14. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
15. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
16. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkins's Disease Staging Classification. Cancer Res 1971;31:1860-1.
17. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
18. Kohno A, Takeyama K, Narabayashi M, Okamoto R, Adachi I, Tobinai K, et al. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplant 1995;15:49-54.
19. Narabayashi M, Takeyama K, Fukutomi T, Tokuda Y, Tajima T, Okumura A, et al. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Jpn J Clin Oncol 1999;29: 285-90.
20. Dunnett C. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-121.
21. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-7.
22. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:2796-802.
23. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-30.
24. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002;20:2472-9.
25. Kaiser U, Uebelaeker I, Havemann K. High dose chemotherapy with autologous stem cell transplantation in high grade NHL: First analysis of a randomized multicenter study. Bone Marrow Transplant 1998; 21(Suppl 1):S177.
26. 2 of CY. Bone Marrow Transplant 1999; 23:421-5.
27. Martin-Murea S, Voso MT, Hohaus S, Pforsich M, Fruehauf S, Goldschmidt H, et al. The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol 1998;101:582-5.
28. Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): A randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002;116:468-74.
29. van Os R, Robinson S, Sheridan T, Mislow JM, Dawes D, Mauch PM. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood 1998;92:1950-6.
30. Charrier S, Chassagne J, Cure H, Bay JO, Communal Y, Portefaix G, et al. Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophosphamide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer. Bone Marrow Transplant 1998;22:845-51.
31. Martinez C, Urbano-Ispizua A, Rozman M, Rovira M, Marin P, Montfort N, et al. Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: Analysis of serial marrow samples from normal donors. Bone Marrow Transplant 1999;23:15-9.
32. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998;103:235-42.
33. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999;17:1227-33.
34. Mitterer M, Hirber J, Gentilini I, Prinoth O, Fabris F, Emmerich B, et al. Target value tailored (TVT) apheresis approach for blood progenitor cell collection after high-dose chemotherapy and rh-G-CSF. Bone Marrow Transplant 1996;18:611-7.